metformin has been researched along with Dilatation, Pathologic in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Dilatation, Pathologic: The condition of an anatomical structure's being dilated beyond normal dimensions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Epidemiological evidence suggests that the antidiabetic drug metformin (MET) can also inhibit abdominal aortic aneurysm (AAA) formation." | 8.02 | Metformin Inhibits Abdominal Aortic Aneurysm Formation through the Activation of the AMPK/mTOR Signaling Pathway. ( Fan, Y; He, J; Hu, X; Li, N; Liu, C; Zhao, X, 2021) |
| "Epidemiological evidence suggests that the antidiabetic drug metformin (MET) can also inhibit abdominal aortic aneurysm (AAA) formation." | 4.02 | Metformin Inhibits Abdominal Aortic Aneurysm Formation through the Activation of the AMPK/mTOR Signaling Pathway. ( Fan, Y; He, J; Hu, X; Li, N; Liu, C; Zhao, X, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| He, J | 1 |
| Li, N | 1 |
| Fan, Y | 1 |
| Zhao, X | 1 |
| Liu, C | 1 |
| Hu, X | 1 |
1 other study available for metformin and Dilatation, Pathologic
| Article | Year |
|---|---|
Metformin Inhibits Abdominal Aortic Aneurysm Formation through the Activation of the AMPK/mTOR Signaling Pathway.
Topics: AMP-Activated Protein Kinases; Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Dilatation, Pa | 2021 |